- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01369199
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B (HBRN)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
To determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B "e" antigen (HBeAg) positive adults who are in the immune tolerant phase.
To evaluate safety and sustained responses after treatment with entecavir and peginterferon alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults who are in the immune tolerant phase.
A single arm treatment study of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon alfa-2a in adults with HBeAg-positive chronic hepatitis B with normal or near normal alanine aminotransferase (ALT) levels and high serum levels of hepatitis B virus (HBV) DNA ("immune tolerant" HBeAg-positive chronic hepatitis B). All participants followed for 48 weeks after treatment discontinuation (week 96 for those who completed treatment).
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5T 2S8
- University of Toronto
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095
- University of California Los Angeles
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars Sinai Medical Center
-
San Francisco, California, Vereinigte Staaten, 94143
- University of California San Francisco
-
San Francisco, California, Vereinigte Staaten, 94115
- California Pacific Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Medical Center
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- NIH Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Health System
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55446
- University of Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University
-
Saint Louis, Missouri, Vereinigte Staaten, 63104
- Saint Louis University
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- University of North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- University of Texas Southwestern
-
Dallas, Texas, Vereinigte Staaten, 75246
- Baylor University Medical Center
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23498
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98101
- Virginia Mason Medical Center
-
Seattle, Washington, Vereinigte Staaten, 98105
- University of Washington Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Enrolled in & completed the baseline evaluation for NCT01263587 or completed the necessary components of NCT01263587 by the end of baseline visit.
- >18 years of age at the baseline visit (day 0). Patients >50 years of age at baseline will need to have a liver biopsy as standard of care with hepatic activity index (HAI) ≤3 & Ishak fibrosis score ≤1 within 96 weeks prior to baseline visit.
- Documented chronic HBV infection as evidenced by detection of HBsAg in serum for ≥24 weeks prior to baseline visit OR at least one positive HBsAg & negative anti-hepatitis B core (HBc) immunoglobulin (IgM) within 24 weeks prior to baseline visit OR at least one positive HBsAg & two positive HBV DNA over a period of ≥24 weeks prior to baseline visit.
- Presence of HBeAg in serum at last screening visit within 6 weeks of baseline visit.
- Serum HBV DNA level >10˄7 IU/mL on at least two occasions at least 12 weeks apart during the 52 weeks before baseline visit. One of the two HBV DNA levels must be within 6 weeks of baseline visit.
- ALT levels persistently ≤45 U/L in males, ≤30 U/L in females (approx. 1.5 times the upper limit of normal (ULN) range) as documented by at least three values: one taken 28-52 weeks before baseline visit, one taken 6 to 24 weeks before the baseline visit, & the final value within 6 weeks prior to baseline visit.
- No evidence of hepatocellular carcinoma (HCC) based upon alpha-fetoprotein (AFP) ≤20 ng/mL at screening visit (up to 6 weeks prior to baseline visit). a. Participants who meet American Association for the Study of Liver Diseases (AASLD) criteria for HCC surveillance must have negative liver imaging as shown by ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI) within 28 weeks prior to baseline visit. b. Participants with AFP >20 ng/mL must be evaluated clinically with additional imaging & shown not to have HCC on CT or MRI before they can be enrolled.
Exclusion Criteria:
- History of hepatic decompensation
- Evidence of decompensated liver disease prior to or during screening, including direct bilirubin >0.5 mg/dL, international normalization ratio (INR) >1.5, or serum albumin <3.5 g/dL.
- Platelet count <120,000/mm3, hemoglobin <13 g/dL (males) or <12 g/dL (females), absolute neutrophil count < 1500 /mm3 (<1000/mm3 for African-Americans) at last screening visit.
- Previous treatment with medications that have established activity against HBV including interferon & nucleos(t)ide analogs ≥24 weeks. Patients with <24 weeks of prior HBV treatment & a wash-out period >24 weeks are not excluded.
- Known allergy or intolerance to study medications.
- Females who are pregnant or breastfeeding. Females of childbearing potential unable or unwilling to use a reliable method of contraception during the treatment period.
- Renal insufficiency with calculated creatinine clearance <50 mL/min at screening.
- History of alcohol or drug abuse within 48 weeks of baseline visit.
- Previous liver or other organ transplantation (including engrafted bone marrow).
- Any other concomitant liver disease, including hepatitis C or D. Non-alcoholic fatty liver disease (NAFLD) with steatosis &/or mild to moderate steatohepatitis is acceptable but NAFLD with severe steatohepatitis is exclusionary.
- Presence of anti-hepatitis D virus (HDV) or anti-hepatitis C virus (HCV) (unless HCV RNA negative) in serum on any occasion in the 144 weeks prior to baseline visit. Presence of anti-HIV (test completed within 6 weeks prior to baseline visit).
- Pre-existing psychiatric condition(s), including, but not limited to: current moderate or severe depression, history of depression requiring hospitalization within the past 10 years, history of suicidal or homicidal attempt within the past 10 years, history of severe psychiatric disorders as determined by a study physician.
- History of immune-mediated or cerebrovascular disease, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, poorly controlled diabetes or uncontrolled seizure disorder, as determined by a study physician.
- Any medical condition that would, in the opinion of a study physician, be predicted to be exacerbated by therapy or that would limit study participation.
- Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids or other immunosuppressive medications during the course of this study.
- Evidence of active or suspected malignancy, or a history of malignancy within the 144 weeks prior to baseline visit (except adequately treated carcinoma in situ or basal cell carcinoma of the skin).
- Expected need for ongoing use of any antivirals with activity against HBV during the course of the study.
- Concomitant use of complementary or alternative medications purported to have antiviral activity.
- Participation in any other clinical trial involving investigational drugs within 30 days of the baseline visit or intention to participate in another clinical trial involving investigational drugs during participation in this study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Peginterferon and entecavir
A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
|
Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Häufigkeit schwerwiegender unerwünschter Ereignisse (SAEs) pro Person und Jahr
Zeitfenster: Von der ersten Behandlung bis zum Ende der Behandlung (bis zu 48 Wochen) und zum Ende der Nachsorge (bis zu 96 Wochen)
|
Die Inzidenz errechnet sich aus der Anzahl der SUE dividiert durch die Anzahl der beobachteten Personenjahre, d. h. die Summe der Jahre zwischen Behandlungsbeginn und Behandlungsende bzw. dem Ende der Nachbeobachtung über alle Teilnehmer hinweg -auf bzw.
|
Von der ersten Behandlung bis zum Ende der Behandlung (bis zu 48 Wochen) und zum Ende der Nachsorge (bis zu 96 Wochen)
|
Proportion of Participants With HBeAg Loss (Lack of Detectable HBeAg) AND HBV DNA ≤1,000 IU/mL
Zeitfenster: End of follow-up (up to 96 weeks)
|
Lack of data was considered to be treatment failure.
|
End of follow-up (up to 96 weeks)
|
Incidence of Adverse Events (AEs) Per Person-Year of Observation
Zeitfenster: From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)
|
The number of AEs includes both AEs and Serious Adverse Events (SAEs).
The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.
|
From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Anteil der Teilnehmer mit HBeAg-Serokonversion
Zeitfenster: Ende der Behandlung (bis zu 48 Wochen)
|
Ende der Behandlung (bis zu 48 Wochen)
|
|
Anteil der Teilnehmer mit HBeAg-Serokonversion
Zeitfenster: Ende der Nachbeobachtung (bis zu 96 Wochen)
|
Ende der Nachbeobachtung (bis zu 96 Wochen)
|
|
Anteil der Teilnehmer mit HBsAg-Serokonversion
Zeitfenster: Ende der Behandlung (bis zu 48 Wochen)
|
Ende der Behandlung (bis zu 48 Wochen)
|
|
Anteil der Teilnehmer mit HBsAg-Serokonversion
Zeitfenster: Ende der Nachbeobachtung (bis zu 96 Wochen)
|
Ende der Nachbeobachtung (bis zu 96 Wochen)
|
|
Anteil der Teilnehmer mit HBV-DNA ≤1000 IE/ml
Zeitfenster: Ende der Behandlung (bis zu 48 Wochen)
|
Ende der Behandlung (bis zu 48 Wochen)
|
|
Anteil der Teilnehmer mit HBV-DNA ≤1000 IE/ml
Zeitfenster: Ende der Nachbeobachtung (bis zu 96 Wochen)
|
Ende der Nachbeobachtung (bis zu 96 Wochen)
|
|
Proportion of Participants With HBeAg Loss
Zeitfenster: End of treatment (up to 48 weeks)
|
End of treatment (up to 48 weeks)
|
|
Proportion of Participants With HBeAg Loss
Zeitfenster: End of follow-up (up to 96 weeks)
|
End of follow-up (up to 96 weeks)
|
|
Proportion of Participants With HBsAg Loss
Zeitfenster: End of treatment (up to 48 weeks)
|
End of treatment (up to 48 weeks)
|
|
Proportion of Participants With HBsAg Loss
Zeitfenster: End of follow-up (up to 96 weeks)
|
End of follow-up (up to 96 weeks)
|
|
Proportion of Participants With Alanine Aminotransferase (ALT) <45 U/L for Men, <30 U/L for Women
Zeitfenster: End of treatment (up to 48 weeks)
|
End of treatment (up to 48 weeks)
|
|
Proportion of Participants With ALT <45 U/L for Men, <30 U/L for Women
Zeitfenster: End of follow-up (up to 96 weeks)
|
End of follow-up (up to 96 weeks)
|
|
Proportion of Participants With ALT Normalization (Men <30 U/L, Women <20 U/L)
Zeitfenster: End of treatment (up to 48 weeks)
|
End of treatment (up to 48 weeks)
|
|
Proportion of Participants With ALT Normalization (Men <30 U/L, Women <20 U/L)
Zeitfenster: End of follow-up (up to 96 weeks)
|
End of follow-up (up to 96 weeks)
|
|
Proportion of Participants With HBV DNA <20 IU/mL
Zeitfenster: End of treatment (up to 48 weeks)
|
End of treatment (up to 48 weeks)
|
|
Proportion of Participants With HBV DNA <20 IU/mL
Zeitfenster: End of follow-up (up to 96 weeks)
|
End of follow-up (up to 96 weeks)
|
|
Absence of Detectable Antiviral Drug-resistance HBV Mutations
Zeitfenster: End of treatment (up to 48 weeks)
|
HBV drug resistance variant testing was performed at the CDC laboratory.
The sequences of the HBV polymerase spanning nucleotide positions 311-1021 were determined by Sanger sequencing.
Drug resistance mutations that were tested in this study included L80VI, L82M, T128N, W153Q, F166L, I169T, V173L, L180M, A181TV, T184ACFGILMS, V191T, A194T, A200V, S202ETV, M204IV, V207I, N236T, M250ILV, and G145R.
|
End of treatment (up to 48 weeks)
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Averell Sherker, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Hauptermittler: Anna Lok, MD, University of Michigan
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, chronisch
- Antiinfektiva
- Antivirale Mittel
- Peginterferon alfa-2a
- Entecavir
Andere Studien-ID-Nummern
- DK082864 HBRN IT Adult Trial
- UL1RR024986 (US NIH Stipendium/Vertrag)
- UL1TR001111 (US NIH Stipendium/Vertrag)
- U01DK082916 (US NIH Stipendium/Vertrag)
- U01DK082864 (US NIH Stipendium/Vertrag)
- U01DK082874 (US NIH Stipendium/Vertrag)
- U01DK082944 (US NIH Stipendium/Vertrag)
- U01DK082843 (US NIH Stipendium/Vertrag)
- U01DK082871 (US NIH Stipendium/Vertrag)
- UL1TR000004 (US NIH Stipendium/Vertrag)
- A-DK-3002-001 (Andere Zuschuss-/Finanzierungsnummer: Interagency agreement with NIDDK)
- U01DK082863 (US NIH Stipendium/Vertrag)
- U01DK082866 (US NIH Stipendium/Vertrag)
- U01DK082867 (US NIH Stipendium/Vertrag)
- U01DK082872 (US NIH Stipendium/Vertrag)
- U01DK082919 (US NIH Stipendium/Vertrag)
- U01DK082923 (US NIH Stipendium/Vertrag)
- U01DK082927 (US NIH Stipendium/Vertrag)
- U01DK082943 (US NIH Stipendium/Vertrag)
- UL1TR000058 (US NIH Stipendium/Vertrag)
- P30DK050306 (US NIH Stipendium/Vertrag)
- M01RR000040 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNoch keine Rekrutierung
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungChronische Hepatitis b | Zirrhose durch Hepatitis BChina
-
Nanfang Hospital of Southern Medical UniversityRekrutierung
-
IlDong Pharmaceutical Co LtdRekrutierungChronische Hepatitis bKorea, Republik von
-
Antios Therapeutics, IncBeendetChronische Hepatitis bVereinigte Staaten
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unbekannt
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi Hospital... und andere MitarbeiterRekrutierungPatienten mit chronischer Hepatitis b stellen nach Absetzen des Nukleosidanalogs auf tAf um (CHANGE)Chronische Hepatitis b | Hepatitis-B-ReaktivierungTaiwan
-
Mahidol UniversityUnbekanntChronische Hepatitis B, HBsAg, Hepatitis-B-ImpfstoffThailand
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntChronische Hepatitis b
-
Tongji HospitalGilead SciencesRekrutierung
Klinische Studien zur Entecavir and peginterferon
-
National Institute of Diabetes and Digestive and...AbgeschlossenHepatitis BVereinigte Staaten, Kanada
-
Third Affiliated Hospital, Sun Yat-Sen UniversityAbgeschlossenAntiviral Treatment of Chronic Hepatitis B
-
National Taiwan University HospitalRoche Pharma AGUnbekanntChronische Hepatitis BTaiwan
-
National Taiwan University HospitalBristol-Myers SquibbUnbekanntChronische Hepatitis BTaiwan
-
National Taiwan University HospitalNational Science Council, TaiwanUnbekanntHepatitis B, chronischTaiwan
-
National Taiwan University HospitalNational Science Council, TaiwanUnbekanntHepatitis B, chronischTaiwan
-
Gangnam Severance HospitalRoche Pharma AGUnbekannt
-
Hoffmann-La RocheAbgeschlossen
-
Ziv HospitalUnbekannt
-
Sun Yat-sen UniversityUnbekannt